References
- 1Dayalu P, Albin RL. Huntington disease: pathogenesis and treatment. Neurol Clin. 2015; 33(1): 101–14. DOI: 10.1016/j.ncl.2014.09.003
- 2Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington’s disease. Mov Disord. 2008; 23(11): 1491–504. DOI: 10.1002/mds.21971
- 3Lieberman AP, Shakkottai VG, Albin RL. Polyglutamine Repeats in Neurodegenerative Diseases. Annu Rev Pathol. 2019; 14: 1–27. DOI: 10.1146/annurev-pathmechdis-012418-012857
- 4Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin Lowering Strategies for Disease Modification in Huntington’s Disease. Neuron. 2019; 101(5): 801–19. DOI: 10.1016/j.neuron.2019.01.039
- 5Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting Huntingtin Expression in Patients with Huntington’s Disease. New England Journal of Medicine; 2019. DOI: 10.1056/NEJMoa1900907
- 6Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration (FDA). The Voice of the Patient: Huntington’s Disease 2016 [Accessed on 4/12/2019]. Available from:
https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM491603.pdf . - 7Simpson JA, Lovecky D, Kogan J, Vetter LA, Yohrling GJ. Survey of the Huntington’s Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs. J Huntingtons Dis. 2016; 5(4): 395–403. DOI: 10.3233/JHD-160228
- 8Albin RL, Burke JF. Potential trade-offs in treatment of premanifest Huntington’s disease. Mov Disord. 2015; 30(10): 1319–23. DOI: 10.1002/mds.26318
- 9Soekhai V, Whichello C, Levitan B, Veldwijk J, Pinto CA, Donkers B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discov Today. 2019; 24(7): 1324–31. DOI: 10.1016/j.drudis.2019.05.001
- 10Jackson WT, Novack TA, Dowler RN. Effective serial measurement of cognitive orientation in rehabilitation: the Orientation Log. Arch Phys Med Rehabil. 1998; 79(6): 718–20. DOI: 10.1016/S0003-9993(98)90051-X
- 11Novack TA, Dowler RN, Bush BA, Glen T, Schneider JJ. Validity of the Orientation Log, relative to the Galveston Orientation and Amnesia Test. J Head Trauma Rehabil. 2000; 15(3): 957–61. DOI: 10.1097/00001199-200006000-00008
- 12Morgan G, Fischhoff B, Bostrom A, Atman C.
Risk Communication: A Mental Models Approach : Cambridge University Press; 2001. DOI: 10.1017/CBO9780511814679 - 13U.S. Department of Health and Human Services Food and Drug Administration. Patient Preference Information – Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling. 2016 [Accessed on 12/2/2020]. Available from:
https://www.fda.gov/media/92593/download . - 14LaDonna KA, Watling CJ, Ray SL, Piechowicz C, Venance SL. Evolving Motivations: Patients’ and Caregivers’ Perceptions About Seeking Myotonic Dystrophy (DM1) and Huntington’s Disease Care. Qual Health Res. 2017; 27(11): 1727–37. DOI: 10.1177/1049732317711901
- 15Unified Huntington’s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996; 11(2): 136–42. DOI: 10.1002/mds.870110204
- 16Downar J, Fowler RA, Halko R, Huyer LD, Hill AD, Gibson JL. Early experience with medical assistance in dying in Ontario, Canada: a cohort study. CMAJ. 2020; 192(8): E173–E81. DOI: 10.1503/cmaj.200016
- 17Ritchie J, Lewis J, Elam G.
Designing and Selecting Samples . In: Ritchie J, Lewis J (eds.), Qualitative research practice: a guide for social science students and researchers. 2003; 77–108. London: Sage Publications. - 18Holt K. What do we tell the children? Contrasting the disclosure choices of two HD families regarding risk status and predictive genetic testing. J Genet Couns. 2006; 15(4): 253–65. DOI: 10.1007/s10897-006-9021-z
- 19Mattsson B, Almqvist EW. Attitudes towards predictive testing in Huntington’s disease--a deep interview study in Sweden. Fam Pract. 1991; 8(1): 23–7. DOI: 10.1093/fampra/8.1.23